If you want a doubler - which could happen out of the blue, (so charts wont be much good here) - try NTP.
To me, this is one of only a few biotechs with any substance. It has already used its particular drug technology to great success with its systemic anti fungal treatment Mycograb. If its MRSA treatment, Aurograb is as effective then the stock will take off like a rocket.
Any success here is likely to be fast tracked by both the FDA and Europe.
NTP is unlike other MRSA "plays" in that it is the only company that has a treatment to offer.
